The association of reduced anti-tumor efficacy by scIgG-T with the decreased number of infiltrated immune cells further suggests that infiltrated mouse immune cells in xenograft tumor tissue are capable of mediating anti-tumor activities when high HER2 expression cancer cells are treated with trastuzumab. This evidence concerns the gene ERBB2 and neoplasm.